Facts and figures

HeadquarterDenmark
InternationalInternational production facilities in seven countries.
Affiliates or offices in 75 countries.
WorkforceApproximately 38,000 employees (January 2014).
Approximately 42% of employees are located in Denmark (15,715) and 58% in the rest of the world (North America: 6,008, Japan & Korea: 1,078, China: 4,549, International Operations: 5,825, Europe: 4,121).
18% within research and development
27% in production and production administration
37% in international sales and marketing
18% in administration
Product areas We have four product areas:
Diabetes care 
Haemostasis management (NovoSeven®) 
Growth hormone therapy 
Hormone replacement therapy (HRT)

According to applicable law, only health care professionals are allowed to access the product information on our site. You can find the information under the Health Care Processionals in the top menu. For patient and disease information, look under Patients. 
Q4 sales*21,698
Annual sales**83,572 (See Annual Report for more information)
Sales by business segment* Diabetes care 17,075
Biopharmaceuticals 4,623
 
Sales by region* Europe 5,185
North America 10,214
International Operations 3,139
China 1,762
Japan & Korea 1,398

Notes
* million Danish kroner, Q4 results 2013
** million Danish kroner, full year results 2013

Novo Nordisk A/S
Bagsv√¶rd, Denmark, 
CVR nr. 24 25 67 90

  •  


  •  
  •  

Share information

Learn more about Novo Nordisk shares.

Shareholder rights


  •  
  •  

Novo Nordisk products

Facts about Novo Nordisk products

Product facts

  •